Research

Hybrid dual aromatase-steroid sulfatase inhibitors with exquisite picomolar inhibitory activity


Reference:

Woo, L. W. L., Bubert, C., Purohit, A. and Potter, B. V. L., 2011. Hybrid dual aromatase-steroid sulfatase inhibitors with exquisite picomolar inhibitory activity. ACS Medicinal Chemistry Letters, 2 (3), pp. 243-247.

Related documents:

This repository does not currently have the full-text of this item.
You may be able to access a copy if URLs are provided below. (Contact Author)

Official URL:

http://dx.doi.org/10.1021/ml100273k

Abstract

Single agents against multiple drug targets are highly topical. Hormone-dependent breast cancer (HDBC) may be more effectively treated by dual inhibition of aromatase and steroid sulfatase (STS), and several dual aromatase-sulfatase inhibitors (DASIs) have been recently reported. The best compounds from two leading classes of DASI, 3 and 9, are low nanomolar inhibitors. In search of a novel class of DASI, core motifs of two leading classes were combined to give a series of hybrid structures, with several compounds showing markedly improved dual inhibitory activities in the picomolar range in JEG-3 cells. Thus, DASIs 14 (IC50: aromatase, 15 pM; STS, 830 pM) and 15 (IC50: aromatase, 18 pM; STS, 130 pM) are the first examples of an exceptional new class of highly potent dual inhibitor that should encourage further development toward multitargeted therapeutic intervention in HDBC.

Details

Item Type Articles
CreatorsWoo, L. W. L., Bubert, C., Purohit, A. and Potter, B. V. L.
DOI10.1021/ml100273k
Uncontrolled Keywordssulfatase, aromatase, hybrid, dual inhibitors, cancer
DepartmentsFaculty of Science > Pharmacy & Pharmacology
RefereedYes
StatusPublished
ID Code23554

Export

Actions (login required)

View Item